Serena Omo-Lamai

Serena Omo-Lamai

Auto-generated profile, based on publicly available information

Serena Omo-Lamai

Department of Bioengineering University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Nature Nanotechnology
Verified
Journal Article
Closed access
SOSerena Omo-Lamai
Serena Omo-Lamai
YWYufei Wang
Yufei Wang
MPManthan N. Patel
Manthan N. Patel
AMAleksa Milosavljevic
Aleksa Milosavljevic
DZDaniel Zuschlag
Daniel Zuschlag
JBJacob S. Brenner
Jacob S. Brenner

13 March 2024 in Advanced Materials
Verified
Journal Article
Open access
SOSerena Omo‐Lamai
Serena Omo‐Lamai
MZMarco E. Zamora
Marco E. Zamora
MPManthan N. Patel
Manthan N. Patel
JWJichuan Wu
Jichuan Wu
JNJia Nong
Jia Nong
JBJacob S. Brenner
Jacob S. Brenner
Lipid nanoparticles (LNPs) have become the dominant drug delivery technology in industry, holding the promise to deliver RNA to up or down‐regulate any protein of interest. LNPs have mostly been targeted to specific cell types or organs by physicochemical targeting in which LNP’s lipid compositions are adjusted to find mixtures with the desired tropism. Here lung‐tropic LNPs are examined, whose organ tropism derives from containing either a cationic or ionizable lipid conferring a positive zeta potential. Surprisingly, these LNPs are found to induce massive thrombosis. Such thrombosis is shown in the lungs and other organs, and it is shown that it is greatly exacerbated by pre‐existing inflammation. This clotting is induced by a variety of formulations with cationic lipids, including LNPs and non‐LNP nanoparticles, and even by lung‐tropic ionizable lipids that do not have a permanent cationic charge. The mechanism depends on the LNPs binding to and then changing the conformation of fibrinogen, which then activates platelets and thrombin. Based on these mechanisms, multiple solutions are engineered that enable positively charged LNPs to target the lungs while ameliorating thrombosis. The findings illustrate how physicochemical targeting approaches must be investigated early for risks and re‐engineered with a careful understanding of biological mechanisms.

18 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SOSerena Omo-Lamai
Serena Omo-Lamai
YWYufei Wang
Yufei Wang
MPManthan N. Patel
Manthan N. Patel
EEEno-Obong Essien
Eno-Obong Essien
MSMengwen Shen
Mengwen Shen
JBJacob S. Brenner
Jacob S. Brenner
Lipid nanoparticles (LNPs) have emerged as the dominant platform for RNA delivery, based on their success in the COVID-19 vaccines and late-stage clinical studies in other indications. However, we and others have shown that LNPs induce severe inflammation, and massively aggravate pre-existing inflammation. Here, using structure-function screening of lipids and analyses of signaling pathways, we elucidate the mechanisms of LNP-associated inflammation and demonstrate solutions. We show that LNPs’ hallmark feature, endosomal escape, which is necessary for RNA expression, also directly triggers inflammation by causing endosomal membrane damage. Large, irreparable, endosomal holes are recognized by cytosolic proteins called galectins, which bind to sugars on the inner endosomal membrane and then regulate downstream inflammation. We find that inhibition of galectins abrogates LNP-associated inflammation, both in vitro and in vivo . We show that rapidly biodegradable ionizable lipids can preferentially create endosomal holes that are smaller in size and reparable by the endosomal sorting complex required for transport (ESCRT) pathway. Ionizable lipids producing such ESCRT-recruiting endosomal holes can produce high expression from cargo mRNA with minimal inflammation. Finally, we show that both routes to non-inflammatory LNPs, either galectin inhibition or ESCRT-recruiting ionizable lipids, are compatible with therapeutic mRNAs that ameliorate inflammation in disease models. LNPs without galectin inhibition or biodegradable ionizable lipids lead to severe exacerbation of inflammation in these models. In summary, endosomal escape induces endosomal membrane damage that can lead to inflammation. However, the inflammation can be controlled by inhibiting galectins (large hole detectors) or by using biodegradable lipids, which create smaller holes that are reparable by the ESCRT pathway. These strategies should lead to generally safer LNPs that can be used to treat inflammatory diseases.

10 June 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SOSerena Omo-Lamai
Serena Omo-Lamai
JNJia Nong
Jia Nong
KSKrupa Savalia
Krupa Savalia
BKBrian J. Kelley
Brian J. Kelley
JWJichuan Wu
Jichuan Wu
JBJacob S. Brenner
Jacob S. Brenner
Traumatic brain injury has faced numerous challenges in drug development, primarily due to the difficulty of effectively delivering drugs to the brain. However, there is a potential solution in targeted drug delivery methods involving antibody-drug conjugates or nanocarriers conjugated with targeting antibodies. Following a TBI, the blood-brain barrier (BBB) becomes permeable, which can last for years and allow the leakage of harmful plasma proteins. Consequently, an appealing approach for TBI treatment involves using drug delivery systems that utilize targeting antibodies and nanocarriers to help restore BBB integrity. In our investigation of this strategy, we examined the efficacy of free antibodies and nanocarriers targeting a specific endothelial surface marker called vascular cell adhesion molecule-1 (VCAM-1), which is known to be upregulated during inflammation. In a mouse model of TBI utilizing central fluid percussion injury, free VCAM-1 antibody did not demonstrate superior targeting when comparing sham vs. TBI brain. However, the administration of VCAM-1-targeted nanocarriers (liposomes) exhibited a 10-fold higher targeting specificity in TBI brain than in sham control. Flow cytometry and confocal microscopy analysis confirmed that VCAM-1 liposomes were primarily taken up by brain endothelial cells post-TBI. Consequently, VCAM-1 liposomes represent a promising platform for the targeted delivery of therapeutics to the brain following traumatic brain injury.

25 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SOSerena Omo-Lamai
Serena Omo-Lamai
MZMarco E. Zamora
Marco E. Zamora
MPManthan N. Patel
Manthan N. Patel
JWJichuan Wu
Jichuan Wu
JNJia Nong
Jia Nong
JBJacob S. Brenner
Jacob S. Brenner
Lipid nanoparticles (LNPs) have become the dominant drug delivery technology in industry, holding the promise to deliver RNA to up- or down-regulate any protein of interest. LNPs have been targeted to specific cell types or organs by physicochemical targeting, in which LNP’s lipid compositions are adjusted to find mixtures with the desired tropism. In a popular approach, physicochemical targeting is accomplished by formulating with charged lipids. Negatively charged lipids localize LNPs to the spleen, and positively charged lipids to the lungs. Here we found that lung-tropic LNPs employing cationic lipids induce massive thrombosis. We demonstrate that thrombosis is induced in the lungs and other organs, and greatly exacerbated by pre-existing inflammation. This clotting is induced by a variety of formulations with cationic lipids, including LNPs and non-LNP nanoparticles. The mechanism depends on the LNPs binding to fibrinogen and inducing platelet and thrombin activation. Based on these mechanisms, we engineered multiple solutions which enable positively charged LNPs to target the lungs while not inducing thrombosis. Our findings implicate thrombosis as a major barrier that blood erects against LNPs with cationic components and illustrate how physicochemical targeting approaches must be investigated early for risks and re-engineered with a careful understanding of biological mechanisms.

24 March 2026 in Advanced Science
Verified
Journal Article
Open access
CECarolann L. Espy
Carolann L. Espy
JWJichuan Wu
Jichuan Wu
SOSerena Omo‐Lamai
Serena Omo‐Lamai
LWLiuqian Wang
Liuqian Wang
FDFengyi Dong
Fengyi Dong
JBJacob S. Brenner
Jacob S. Brenner
Lipid nanoparticles (LNPs) are widely used for nucleic acid delivery, yet their clinical utility is limited by an acute inflammatory response post‐administration. LNP‐associated inflammation (LAI) manifests as de novo inflammation in select organs (e.g., in the lungs after inhalation) and severely worsens pre‐existing inflammation. NF‐κB is a key transcription factor mediating this inflammation and represents a promising target for LAI mitigation strategies. However, systemic NF‐κB inhibition carries risks of global immunosuppression, highlighting the need for localized inhibition. Here, we screen a panel of direct and indirect small molecule inhibitors of NF‐κB for their ability to reduce LAI without disrupting LNPs’ expression. We identify inhibitors that load efficiently into LNPs, retain anti‐inflammatory activity in vitro and in vivo, and preserve expression of cargo mRNA in target tissues. Our results demonstrate that co‐formulation of NF‐κB inhibitors with cargo nucleic acids enables localized immunomodulation in LNPs, offering a modular strategy to enhance the safety profile of LNPs for therapeutic use in inflammatory or high‐risk patient populations.